A recent Federal Circuit ruling in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal Pharms. of N.Y., LLC is poised to significantly reshape the landscape of Orange Book patent listings and Hatch-Waxman litigation, according to a new analysis by Gregory J. Glover, MD JD, author of Regulatory…
Federal Circuit Ruling Potentially Upends Orange Book Patent Listing Requirements, Expert Analysis Reveals
This post was originally published on this site